Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the successful closure of a Series A++ financing round worth USD 10 million. The round was led by Med-Fine Capital, with participation from Puhua Leading Investment. The funds raised will be allocated towards the global promotion of the company’s micro RF product lines and to support regulatory filings in the Middle East, the US, and Europe.
Rebecca Tech’s micro RF technology has demonstrated significant clinical efficacy in treating overactive bladder (OAB). The company’s OAB micro RF therapeutic device, which was the world’s first to receive approval for the China market in 2020, utilizes a disposable catheter in conjunction with micro RF equipment for neuroradiofrequency treatment of the bladder neck, designed to reduce neurosensitivity. According to clinical data, the product has achieved a 74% improvement rate in OAB symptoms, with considerable improvements in urinary frequency, urgency, and nocturia frequency. Notably, as this procedure does not require cystoscopy, it significantly reduces the learning curve, making it highly accessible and expected to rapidly gain coverage in grassroots hospitals.
In addition to its medical applications, Rebecca Tech’s NEBULYFT Micro RF cosmetic instrument has obtained professional certifications in Europe and the US, highlighting the company’s broad potential in both medical and aesthetic markets.- Flcube.com
